Table: Daito -Q1 group results
Oct 12 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Aug 31, 2016 Aug 31, 2015 May 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 9.11 8.73 38.10
(+4.3 pct) (+17.7 pct) (+4.8 pct)
Operating 929 mln 968 mln 3.70
(-4.0 pct) (+35.0 pct) (+4.1 pct)
Recurring 967 mln 1.01 3.75
(-4.0 pct) (+40.9 pct) (+1.0 pct)
Net 671 mln 678 mln 2.60
(-1.0 pct) (+48.6 pct) (+1.3 pct)
EPS 53.67 yen 54.23 yen 207.76 yen
Ann Div 30.00 yen 30.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 15.00 yen 15.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results